Who is sponsoring NCT00857948?

NCT00857948 is sponsored by Topaz Pharmaceuticals Inc.

What drugs are being tested in NCT00857948?

Interventions in NCT00857948: ivermectin treatment conditioner, Placebo, vehicle control.

What condition does NCT00857948 study?

NCT00857948 studies Pediculus Humanus Capitis (Head Lice).

Is NCT00857948 still recruiting?

NCT00857948 is currently completed. Last updated 1 March 2012.

Are results published for NCT00857948?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2012-03-01 · How we verify

NCT00857948

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of 3 Strengths of Ivermectin Treatment Conditioner and Placebo in Subjects With Pediculus Humanus Capitis (Head Lice) Infestation

Completed Phase 2 Results posted Last updated 1 March 2012

What this trial tests

Phase 2 trial testing ivermectin treatment conditioner in Pediculus Humanus Capitis (Head Lice) in 78 participants. Completed in 1 April 2009.

Timeline

1 March 2009

Primary endpoint
1 April 2009

1 April 2009

Quick facts

Lead sponsor	Topaz Pharmaceuticals Inc
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	78
Start date	1 March 2009
Primary completion	1 April 2009
Estimated completion	1 April 2009
Sites	1 location across United States

Drugs / interventions tested

ivermectin treatment conditioner — full drug profile →
Placebo, vehicle control — full drug profile →

Conditions studied

Pediculus Humanus Capitis (Head Lice) — all drugs for Pediculus Humanus Capitis (Head Lice) →

Sponsor

Topaz Pharmaceuticals Inc — full company profile →

Who can join

6 Months and older, any sex, with Pediculus Humanus Capitis (Head Lice). Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Percentage of Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control)
Time frame: Day 1 through Day 15 post-application
Live lice eradication was assessed by visual checks of hair and scalp on Days 1, 2 and 8 and by visual checks and counting both live and dead lice from rinse water on Day 15. Eradication was defined as cessation of motility (antennae and leg movement) in all lice.

Sponsor's own description

This is a Phase 2 single center study designed to compare the safety, local tolerability, and efficacy of 3 strengths of ivermectin treatment conditioner to placebo.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00857948 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Topaz Pharmaceuticals Inc
Last refreshed: 1 March 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00857948.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing